The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Open accessAbstract
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Chronic IFN signaling can also promote an immune suppressive environment126.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [126]
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“In solid tumors, a tumor IFN–stimulated gene signature termed ISG.RS is associated with a multigenic program of T-cell exhaustion and worse outcomes after immune checkpoint blockade.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“One part of this program is to increase tumor expression of multiple T-cell ligands that lead to exhaustion of T cells infiltrating the TME.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“Recently, the Minn group elucidated how chronic IFN signaling mediates immunosuppression and resistance to radiation and immune checkpoint inhibitor therapy in solid tumors.2,24,54”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“interferon signaling is of central importance to antitumor immune response43.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Cited by
Sorted by citations
Items 201–300 of 1,000
A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
Liang, S., Tran, E., Du, X., Dong, J., Sudholz, H., Chen, H., Qu, Z., Huntington, N. D., Babon, J. J., Kershaw, N. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40170-8 · Cited by 100
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy
Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 102
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95
Tumor-associated macrophage heterogeneity is driven by tissue territories in breast cancer
Laviron, M., Petit, M., Weber-Delacroix, E., Combes, A. J., Arkal, A. R., Barthélémy, S., Courau, T., Hume, D. A., Combadière, C., Krummel, M. F., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110865 · Cited by 102
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Luo, N., Formisano, L., Ericsson, P. I. G., Sanchez, V. M., Dean, P. T., Opalenik, S. R., Sanders, M. E., Cook, R. S., Arteaga, C. L., Johnson, D. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438106 · Cited by 94
Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0527-7 · Cited by 90
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell
Shao, L., Hou, W., Scharping, N. E., Vendetti, F. P., Srivastava, R., Roy, C. N., Menk, A. V., Wang, Y., Chauvin, J.-M., Karukonda, P., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0711 · Cited by 90
Association ofMUC16Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
Zhang, L., Han, X., & Shi, Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13201 · Cited by 89
Zhang, F., Zhang, Q., Zhu, J., Yao, B., Ma, C., Qiao, N., He, S., Ye, Z., Wang, Y., Han, R., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00736-5 · Cited by 93
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 90
Extracellular vesicles as antigen carriers for novel vaccination avenues
Mehanny, M., Lehr, C., & Fuhrmann, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.016 · Cited by 93
JAK inhibitors: Ten years after
Spinelli, F. R., Meylan, F., O’Shea, J. J., & Gadina, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202048922 · Cited by 91
Gerace, D., Zhou, Q., Kenty, J. H.-R., Veres, A., Sintov, E., Wang, X., Boulanger, K. R., Li, H., & Melton, D. A. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100879 · Cited by 88
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 98
Mills, B. N., Connolly, K. A., Ye, J., Murphy, J. D., Uccello, T. P., Han, B. J., Zhao, T., Drage, M. G., Murthy, A., Qiu, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.095 · Cited by 88
Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation
Luo, Z., Liang, X., He, T., Qin, X., Li, X., Li, Y., Li, L., Loh, X. J., Gong, C., & Liu, X. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c03266 · Cited by 87
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
Torrano, J., Emran, A. A., Hammerlindl, H., & Schaider, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0644-y · Cited by 87
Gupta, R., Malvi, P., Parajuli, K. R., Janoštiak, R., Bugide, S., Cai, G., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005156117 · Cited by 85
Type I interferons and related pathways in cell senescence
Frisch, S. M., & MacFawn, I. (2020) · Aging Cell · doi:10.1111/acel.13234 · Cited by 89
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
Dougan, M. L., Ingram, J. R., Jeong, H., Mosaheb, M. M., Bruck, P. T., Ali, L. R., Pishesha, N., Blomberg, O. S., Tyler, P. M., Servos, M. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0495 · Cited by 85
Pedersen, M. H., Hood, B. L., Beck, H. C., Conrads, T. P., Ditzel, H. J., & Leth‐Larsen, R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1305531 · Cited by 88
Chromatin dependencies in cancer and inflammation
Marazzi, I., Greenbaum, B. D., Low, D. H. P., & Guccione, E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.113 · Cited by 80
Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression
Curdy, N., Lanvin, O., Laurent, C., Fournié, J., & Franchini, D. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.002 · Cited by 84
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
STING signaling is a potential immunotherapeutic target in colorectal cancer
Chon, H. J., Kim, H., Noh, J. H., Yang, H., Lee, W. S., Kong, S. J., Lee, S., Lee, Y. S., Kim, W. R., Kim, J. H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.32806 · Cited by 83
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 78
Zhou, B., Gao, Y., Zhang, P., & Chu, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693609 · Cited by 81
Activating Innate Immunity by a STING Signal Amplifier for Local and Systemic Immunotherapy
Song, W. L., Song, S., Kuang, J., Yang, H., Yu, T., Yang, F., Wan, T. Y., Xu, Y., Wei, S., Li, M.-X., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c03509 · Cited by 78
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Yuan, S., Sun, R., Shi, H., Chapman, N. M., Hu, H., Guy, C. S., Rankin, S. L., Anil, K. C., Palacios, G., Meng, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08732-6 · Cited by 82
Drakes, M. L., Mehrotra, S., Aldulescu, M., Potkul, R. K., Liu, Y., Grisoli, A., Joyce, C., O’Brien, T. E., Stack, M. S., & Stiff, P. J. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0414-z · Cited by 79
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Yan, S., Wang, W., Feng, Z., Xue, J., Liang, W., Wu, X., Tan, Z., Zhang, X., Zhang, S., Li, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403533 · Cited by 83
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M. R., Barnes, J. M., Tanlimco, S. G., Lu, R. O., Halliwill, K. D., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 76
Cheng, X., Fan, K., Wang, L., Ying, X., Sanders, A. J., Guo, T., Xing, X., Zhou, M., Du, H., Hu, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2272-z · Cited by 75
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy
Shang, Q., Dong, Y., Su, Y., Leslie, F., Sun, M., & Wang, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114308 · Cited by 74
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 76
Escape from T-cell–targeting immunotherapies in acute myeloid leukemia
Vadakekolathu, J. N., & Rutella, S. (2023) · Blood · doi:10.1182/blood.2023019961 · Cited by 77
Cheng, Y., Chen, X., Li, F., Yang, Z., Xiao, L., Xiang, B., Wang, X., Liu, D., Lin, P., Shi, J.-Y., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00747-z · Cited by 80
Ma, H., Yang, W., Zhang, L., Liu, S., Zhao, M., Zhou, G., Wang, L., Jin, S., Zhang, Z., & Hu, J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0352-y · Cited by 79
Saleiro, D., & Platanias, L. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101299 · Cited by 76
Radiotherapy: Brightness and darkness in the era of immunotherapy
Zhai, D., An, D., Wan, C., & Yang, K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101366 · Cited by 73
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
Mo, X., Niu, Q., Ivanov, A. A., Tsang, Y. H., Tang, C., Shu, C., Li, Q., Qian, K., Wahafu, A., Doyle, S. P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.014 · Cited by 73
Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0686 · Cited by 78
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Ma, K.-Y., Schonnesen, A. A., Brock, A., Berg, C. V. D., Eckhardt, S. G., Liu, Z., & Jiang, N. J. (2019) · JCI Insight · doi:10.1172/jci.insight.121387 · Cited by 74
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus
Mineo, M., Lyons, S. M., Zdioruk, M. I., von Spreckelsen, N., Ferrer-Luna, R., Ito, H., Alayo, Q. A., Kharel, P., Giantini-Larsen, A., Fan, W. Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.015 · Cited by 70
Halloran, P. F., Venner, J. M., & Famulski, K. S. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14200 · Cited by 72
Sabbatino, F., Marra, A., Liguori, L., Scognamiglio, G., Fusciello, C., Botti, G., Ferrone, S., & Pepe, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0439-2 · Cited by 71
Du, S., Chen, G., Yuan, B., Hu, Y., Yang, P., Chen, Y., Zhao, Q., Zhou, J., Fan, J., & Zeng, Z. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0395-x · Cited by 70
Immune checkpoint receptors: homeostatic regulators of immunity
Riva, A., & Chokshi, S. (2018) · Hepatology International · doi:10.1007/s12072-018-9867-9 · Cited by 71
Sethuraman, S. N., Singh, M. P., Patil, G., Li, S., Fiering, S., Hoopes, P. J., Guha, C., Malayer, J. R., & Ranjan, A. (2020) · Theranostics · doi:10.7150/thno.42243 · Cited by 70
What, Why, Where, and When: Bringing Timing to Immuno-Oncology
Rothschilds, A. M., & Wittrup, K. D. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.003 · Cited by 68
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 73
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 71
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Liu, C., Kieltyka, J., Fleischmann, R., Gadina, M., & O’Shea, J. J. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41906 · Cited by 69
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 67
Chen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 66
Fan, J.-B., Miyauchi, S., Xu, H., Liu, D., Kim, L. J. Y., Burkart, C., Cheng, H., Arimoto, K., Yan, M., Zhou, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0608 · Cited by 63
Oncolytic Virotherapy: From Bench to Bedside
Yang, L., Gu, X., Yu, J., Ge, S., & Fan, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790150 · Cited by 69
Lei, P., Pereira, E. R., Andersson, P., Amoozgar, Z., van Wijnbergen, J. W., O’Melia, M. J., Zhou, H., Chatterjee, S., Ho, W. W., Posada, J. M., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221847 · Cited by 71
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 68
Xia, L., Zheng, Z., Liu, J., Chen, Y.-J., Ding, J., Hu, G.-S., Hu, Y.-H., Liu, S., Luo, W., Xia, N., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0405 · Cited by 65
Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153990 · Cited by 68
Gadina, M., Chisolm, D. A., Philips, R. L., McInness, I. B., Changelian, P. S., & O’Shea, J. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901477 · Cited by 67
Antecedent chromatin organization determines cGAS recruitment to ruptured micronuclei
MacDonald, K. M., Nicholson-Puthenveedu, S., Tageldein, M. M., Khasnis, S., Arrowsmith, C. H., & Harding, S. M. (2023) · Nature Communications · doi:10.1038/s41467-023-36195-8 · Cited by 66
Rejeski, K., Perez, A. P., Iacoboni, G., Blumenberg, V., Bücklein, V., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3919 · Cited by 64
Regulation of human interferon signaling by transposon exonization
Pasquesi, G. I. M., Allen, H. L., Ivancevic, A. M., Barbachano-Guerrero, A., Joyner, O., Guo, K., Simpson, D. M., Gapin, K., Horton, I., Nguyen, L. L., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.016 · Cited by 67
Zuo, X., Deguchi, Y., Xu, W., Liu, Y., Li, H. S., Wei, D., Tian, R., Chen, W., Xu, M., Yang, Y., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.018 · Cited by 63
Panagioti, E., Kurokawa, C., Viker, K., Ammayappan, A., Anderson, S., Sotiriou, S., Chatzopoulos, K., Ayasoufi, K., Johnson, A. J., Iankov, I., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141614 · Cited by 56
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 66
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille‐Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 63
Tiffen, J. C., Gallagher, S. J., Filipp, F. V., Gunatilake, D., Emran, A. A., Cullinane, C. M., Dutton‐Regester, K., Aoude, L. G., Hayward, N. K., Chatterjee, A., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.02.042 · Cited by 64
Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Jaeger, A. M., Stopfer, L. E., Lee, S., Gaglia, G., Sandel, D. A., Santagata, S., Lin, N., Trepel, J. B., White, F. M., Jacks, T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0596 · Cited by 61
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 67
Preedy, M. K., White, M., & Tergaonkar, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06559-z · Cited by 69
Nakamura, K., Karmokar, A., Farrington, P. M., James, N. H., Ramos‐Montoya, A., Bickerton, S. J., Hughes, G. D., Illidge, T., Cadogan, E. B., Davies, B. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3701 · Cited by 60
Bashash, D., Zandi, Z., Kashani, B., Pourbagheri‐Sigaroodi, A., Salari, S., & Ghaffari, S. H. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30575 · Cited by 62
DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
Chen, B., Hu, J., Hu, X., Chen, H., Bao, R., Zhou, Y., Ye, Y., Zhan, M., Cai, W., Li, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29754-y · Cited by 61
Cheruku, S., Rao, V., Pandey, R., Chamallamudi, M. R., Ravichandiran, V., & Kumar, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109569 · Cited by 63
Dixon, M. L., Luo, L., Ghosh, S., Grimes, J. M., Leavenworth, J. D., & Leavenworth, J. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01450-3 · Cited by 57
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Traets, J. J. H., Altimari, D. M. D., Vliet, A. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29442-x · Cited by 59
Molecular determinants of immunogenic cell death elicited by radiation therapy
Galassi, C., Klapp, V., Yamazaki, T., & Galluzzi, L. (2023) · Immunological Reviews · doi:10.1111/imr.13271 · Cited by 65
Li, F., Yang, Z., Savage, T. M., Vincent, R. L., Santos, K. D. L., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn9879 · Cited by 59
Cancer vaccines: platforms and current progress
Lei, W., Zhou, K., Lei, Y., Qiu, L., & Zhu, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00241-8 · Cited by 66
The immunological consequences of radiation‐induced DNA damage
Wilkins, A. C., Patin, E. C., Harrington, K. J., & Melcher, A. A. (2019) · The Journal of Pathology · doi:10.1002/path.5232 · Cited by 60
Theivanthiran, B., Yarla, N. S., Haykal, T., Nguyen, Y., Cao, L., Ferreira, M., Holtzhausen, A., Al-Rohil, R. N., Salama, A. K. S., Beasley, G. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq7019 · Cited by 58
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies
Frydenlund, N., & Mahalingam, M. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.06.012 · Cited by 62
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
Halabi, L. E., Adam, J., Gravelle, P., Marty, V., Danu, A., Lazarovici, J., Ribrag, V., Bosq, J., Camara‐Clayette, V., Laurent, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.009 · Cited by 59
Zhu, C., Zou, C., Guan, G., Guo, Q., Yan, Z., Liu, T., Shen, S., Xu, X., Chen, C., Lin, Z., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1621677 · Cited by 55
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 60
Goh, P. K., Wiede, F., Zeissig, M. N., Britt, K. L., Liang, S., Molloy, T., Goode, N., Xu, R., Loi, S., Müller, M. M., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk3338 · Cited by 56
Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment
Roussot, N., Ghiringhelli, F., & Rébé, C. (2022) · Cells · doi:10.3390/cells11223672 · Cited by 55
Liu, Y., Kimpara, S., Hoang, N. M., Daenthanasanmak, A., Li, Y., Lü, L., Ngo, V. N., Bates, P. D., Song, L., Gao, X., et al. (2023) · Blood · doi:10.1182/blood.2023020142 · Cited by 56
Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 62
Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 66
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 56
A Dual Role of Type I Interferons in Antitumor Immunity
Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 62
Yi, X., Wang, H., Yang, Y., Wang, H., Zhang, H., Guo, S., Chen, J., Du, J., Tian, Y., Ma, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01314-w · Cited by 55
Metadata
- Authors
- Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., Gangadhar, T. C., Amaravadi, R. K., Schuchter, L. M., Feldman, M. D., Ishwaran, H., Vonderheide, R. H., Maity, A., Wherry, E. J., & Minn, A. J.
- Affiliations
- University of Pennsylvania (US)
- University of Miami (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Minn, Andy J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1540-1554.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5385895
- OpenAlex
- W2558219863
- Cited by
- 1,216
- References
- 42
- Citations by year
- 2026: 150 · 2025: 124 · 2024: 127 · 2023: 135 · 2022: 128 · 2021: 140 · 2020: 140 · 2019: 114 · 2018: 92 · 2017: 64 · 2016: 1
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo
- Funders
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- Robertson Foundation
- Cancer Research Institute Irvington Fellowship
- NIH (P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521)
- Basser Research Center for BRCA
- Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer
- Department of Defense Era of Hope Scholar (W81XWH-09-1-0339)
- NCI (R01CA172651)
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitor resistance, type I interferon, interferon-gamma, PD-1 pathway, PD-L1, STAT1, interferon-stimulated genes, T cell inhibitory receptors, T cell exhaustion, radiotherapy, tumor immune microenvironment, resistance biomarkers, anti-PD-1 therapy
- MeSH terms
- Animals, Humans, Interferons, Melanoma, Neoplasm Transplantation, T-Lymphocytes, Radioimmunotherapy, Drug Resistance, Neoplasm, Cell Line, Tumor, STAT1 Transcription Factor, Mice, B7-H1 Antigen, CTLA-4 Antigen, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
